SUPRIYA
Supriya Lifescience Limited (SUPRIYA) Stock Analysis
Supriya Lifescience Limited manufactures active pharmaceutical ingredients for global markets across therapeutic categories. It supplies APIs with USFDA and EU approved facilities from Maharashtra plants. The company focuses on regulated market exports and contract manufacturing. It is listed on Indian stock exchanges.
Healthcare › Biotechnology
₹847.60
-8.95% 1W | +23.40% 52W
Market Cap
6.8k CR
P/E Ratio
34.4
52W High
₹1085
52W Low
₹545.5
Div. Yield
0.12%
Beta
0.6
50 DMA
₹875.8
200 DMA
₹774.9
Profit Margin
22.7%
Inst. Own.
4.9%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Expenses | 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 |
| Operating Profit | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 |
| OPM % | 34% | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% |
| Other Income | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before tax | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 33% | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% |
| Net Profit | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS in Rs | 3.54 | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Expenses | 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 533 | 583 |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 295 | 290 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% | 33% |
| Other Income | 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 | 11 |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 3 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 | 31 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 | 268 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | 24% | |
| Net Profit | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 | 24.65 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% | 4% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 22.0% | 16.0% | – |
| Profit CAGR | 32.0% | 11.0% | – |
Shareholding Pattern
Promoters68.30%
FIIs6.78%
DIIs4.86%
Public20.08%
Promoters68.30%
FIIs5.46%
DIIs5.22%
Public21.02%
Promoters68.30%
FIIs5.19%
DIIs5.00%
Public21.49%
Promoters68.30%
FIIs5.16%
DIIs5.70%
Public20.83%
Promoters68.30%
FIIs6.18%
DIIs5.30%
Public20.21%
Promoters68.28%
FIIs5.66%
DIIs7.65%
Public18.43%
Promoters68.30%
FIIs5.37%
DIIs5.30%
Public21.04%
Promoters68.30%
FIIs7.19%
DIIs4.26%
Public20.25%
Promoters68.30%
FIIs5.16%
DIIs5.70%
Public20.83%
Promoters68.30%
FIIs6.18%
DIIs5.30%
Public20.21%
SUPRIYA
Holdings Analysis
Key strengths & risk signals
83
Overall
86
Fundamental
81
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.12% yield - little to no income.
RECOVERY MODE! Current price (847.6) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 8.9% (1 week), 7.0% (1 month), 0.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (875.8) is above 200-day average (774.9) - positive signal.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 412,474 vs down days: 228,960. Ratio: 1.8x
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
83Overall
86Fundamental
81Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 21.2% (EXCELLENT, 15/15). Profit CAGR: 32.5% (EXCELLENT, 15/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 22.7% profit margin - company keeps strong profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.06 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.12% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 18.43% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (875.8) is above 200-day average (774.9) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (847.6) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
8/10
GOOD YEAR! Stock gained 23.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 412,474 vs down days: 228,960. Ratio: 1.8x
RSI
4/5
APPROACHING OVERSOLD! RSI at 39.7 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 56.0% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 8.9% (1 week), 7.0% (1 month), 0.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
SUPRIYA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-02 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-18 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
| CONCORDBIO | ₹1,361.40 | 46.9 | 24.8% | 8.0% | 2.8% | -15.2% | 58 | BOUNCE FROM SUPPORT | +30.8% | -35.0% | +26.2% | -21.0% |
| ONESOURCE | ₹1,461.30 | – | -3.1% | 232.4% | – | -18.3% | 44 | BREAKDOWN | -12,600.0% | +443.5% | +37.2% | +4.9% |
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
Data from TradeAlone · Updated daily
SUPRIYA News
Supriya Lifescience Limited (SUPRIYA) falls 6% intraday2026-08-11Supriya Lifescience Limited (SUPRIYA) breaks below support, moves down 10% intraday2026-07-06Supriya Lifescience Limited (SUPRIYA) breaks below support, falls 5%2026-07-06Supriya Lifescience Limited (NSE: SUPRIYA) extends gains, moves up 6% intraday2026-06-30Supriya Lifescience Limited (NSE: SUPRIYA) extends gains, moves up 5% intraday2026-06-23Supriya Lifescience Limited (supriya) Q4 FY26: Revenue Surges 50% Yoy2026-05-28
